questionsmedicales.fr
Structures virales
Virion
Virion : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Tests de diagnostic
Virion
Microscopie électronique
Virus
Tests sérologiques
Anticorps
Symptômes
5
Infection virale
Symptômes
Variabilité des symptômes
Virus
Période d'incubation
Infection virale
Symptômes neurologiques
Virus
Prévention
5
Masques
Transmission virale
Hygiène personnelle
Prévention
Traitements
5
Antibiotiques
Infection virale
Traitement symptomatique
Infection virale
Résistance virale
Antiviraux
Complications
5
Complications
Infection virale
Maladies chroniques
Virus
Gestion des complications
Traitement
Variabilité des complications
Virus
Facteurs de risque
5
Facteurs de risque
Infection virale
Stress
Système immunitaire
Maladies chroniques
Infection virale
Environnement
Infection virale
Habitudes alimentaires
Système immunitaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Virion : Questions médicales les plus fréquentes",
"headline": "Virion : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Virion : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-12",
"dateModified": "2025-03-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Virion"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Structures virales",
"url": "https://questionsmedicales.fr/mesh/D056224",
"about": {
"@type": "MedicalCondition",
"name": "Structures virales",
"code": {
"@type": "MedicalCode",
"code": "D056224",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A21"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Nucléocapside",
"alternateName": "Nucleocapsid",
"url": "https://questionsmedicales.fr/mesh/D019251",
"about": {
"@type": "MedicalCondition",
"name": "Nucléocapside",
"code": {
"@type": "MedicalCode",
"code": "D019251",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A21.249.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Capside",
"alternateName": "Capsid",
"url": "https://questionsmedicales.fr/mesh/D002213",
"about": {
"@type": "MedicalCondition",
"name": "Capside",
"code": {
"@type": "MedicalCode",
"code": "D002213",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A21.249.500.250"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Enveloppe virale",
"alternateName": "Viral Envelope",
"url": "https://questionsmedicales.fr/mesh/D000086942",
"about": {
"@type": "MedicalCondition",
"name": "Enveloppe virale",
"code": {
"@type": "MedicalCode",
"code": "D000086942",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A21.249.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Virion",
"alternateName": "Virion",
"code": {
"@type": "MedicalCode",
"code": "D014771",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Tibor Füzik",
"url": "https://questionsmedicales.fr/author/Tibor%20F%C3%BCzik",
"affiliation": {
"@type": "Organization",
"name": "Structural Virology Group, Central European Institute of Technology, Masaryk University, Kamenice 753/5, 62500 Brno, Czech Republic."
}
},
{
"@type": "Person",
"name": "Pavel Plevka",
"url": "https://questionsmedicales.fr/author/Pavel%20Plevka",
"affiliation": {
"@type": "Organization",
"name": "Structural Virology Group, Central European Institute of Technology, Masaryk University, Kamenice 753/5, 62500 Brno, Czech Republic pavel.plevka@ceitec.muni.cz."
}
},
{
"@type": "Person",
"name": "Liya Mukhamedova",
"url": "https://questionsmedicales.fr/author/Liya%20Mukhamedova",
"affiliation": {
"@type": "Organization",
"name": "Structural Virology Group, Central European Institute of Technology, Masaryk University, Kamenice 753/5, 62500 Brno, Czech Republic."
}
},
{
"@type": "Person",
"name": "Antonín Přidal",
"url": "https://questionsmedicales.fr/author/Anton%C3%ADn%20P%C5%99idal",
"affiliation": {
"@type": "Organization",
"name": "Department of Zoology, Fishery, Hydrobiology, and Apidology, Faculty of Agronomy, Mendel University in Brno, Zemědělská 1/1665, 613 00 Brno, Czech Republic."
}
},
{
"@type": "Person",
"name": "Michael Way",
"url": "https://questionsmedicales.fr/author/Michael%20Way",
"affiliation": {
"@type": "Organization",
"name": "Cellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London, United Kingdom."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Oxaliplatin (3 months",
"datePublished": "2022-06-30",
"url": "https://questionsmedicales.fr/article/35772045",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1200/JCO.21.02962"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interactions with DNA Models of the Oxaliplatin Analog (",
"datePublished": "2024-07-05",
"url": "https://questionsmedicales.fr/article/39000496",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25137392"
}
},
{
"@type": "ScholarlyArticle",
"name": "Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With",
"datePublished": "2022-06-06",
"url": "https://questionsmedicales.fr/article/35666229",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1200/JCO.22.00839"
}
},
{
"@type": "ScholarlyArticle",
"name": "Unusual stroke-like symptoms with oxaliplatin use.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37323007",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10781552231181525"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.",
"datePublished": "2022-10-17",
"url": "https://questionsmedicales.fr/article/36252550",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000527012"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Structures virales",
"item": "https://questionsmedicales.fr/mesh/D056224"
},
{
"@type": "ListItem",
"position": 3,
"name": "Virion",
"item": "https://questionsmedicales.fr/mesh/D014771"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Virion - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Virion",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Virion",
"description": "Comment identifier un virion dans un échantillon ?\nQuels tests sont utilisés pour détecter les virions ?\nLes virions peuvent-ils être visualisés au microscope ?\nQuelle est la méthode de culture des virions ?\nLes tests sérologiques détectent-ils les virions ?",
"url": "https://questionsmedicales.fr/mesh/D014771?mesh_terms=Oxaliplatin#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Virion",
"description": "Quels symptômes indiquent une infection virale ?\nLes virions causent-ils toujours des symptômes ?\nComment les symptômes varient-ils selon le virion ?\nLes symptômes d'une infection virale sont-ils immédiats ?\nLes virions peuvent-ils provoquer des symptômes neurologiques ?",
"url": "https://questionsmedicales.fr/mesh/D014771?mesh_terms=Oxaliplatin#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Virion",
"description": "Comment prévenir les infections virales ?\nLes masques protègent-ils contre les virions ?\nLes vaccins sont-ils efficaces contre tous les virions ?\nL'hygiène personnelle aide-t-elle à prévenir les infections ?\nLes voyages augmentent-ils le risque d'infection virale ?",
"url": "https://questionsmedicales.fr/mesh/D014771?mesh_terms=Oxaliplatin#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Virion",
"description": "Quels traitements sont efficaces contre les virions ?\nLes antibiotiques sont-ils efficaces contre les virions ?\nComment les vaccins agissent-ils contre les virions ?\nLes traitements symptomatiques sont-ils utiles ?\nLes traitements antiviraux sont-ils toujours efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D014771?mesh_terms=Oxaliplatin#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Virion",
"description": "Quelles complications peuvent survenir après une infection virale ?\nLes virions peuvent-ils causer des maladies chroniques ?\nComment les complications sont-elles gérées ?\nLes complications varient-elles selon le virion ?\nLes enfants sont-ils plus à risque de complications ?",
"url": "https://questionsmedicales.fr/mesh/D014771?mesh_terms=Oxaliplatin#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Virion",
"description": "Quels sont les facteurs de risque d'infection virale ?\nLe stress affecte-t-il le risque d'infection virale ?\nLes maladies chroniques augmentent-elles le risque d'infection ?\nL'environnement joue-t-il un rôle dans le risque viral ?\nLes habitudes alimentaires influencent-elles le risque viral ?",
"url": "https://questionsmedicales.fr/mesh/D014771?mesh_terms=Oxaliplatin#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un virion dans un échantillon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par microscopie électronique ou tests PCR."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les virions ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests PCR, les cultures virales et les tests sérologiques sont courants."
}
},
{
"@type": "Question",
"name": "Les virions peuvent-ils être visualisés au microscope ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les virions peuvent être visualisés au microscope électronique."
}
},
{
"@type": "Question",
"name": "Quelle est la méthode de culture des virions ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les virions sont cultivés dans des cellules hôtes appropriées en laboratoire."
}
},
{
"@type": "Question",
"name": "Les tests sérologiques détectent-ils les virions ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils détectent les anticorps contre les virions, pas les virions eux-mêmes."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une infection virale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, fatigue, douleurs musculaires et symptômes respiratoires sont fréquents."
}
},
{
"@type": "Question",
"name": "Les virions causent-ils toujours des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains virions peuvent être asymptomatiques chez l'hôte."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon le virion ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent du type de virus et de l'hôte infecté."
}
},
{
"@type": "Question",
"name": "Les symptômes d'une infection virale sont-ils immédiats ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il peut y avoir une période d'incubation avant l'apparition des symptômes."
}
},
{
"@type": "Question",
"name": "Les virions peuvent-ils provoquer des symptômes neurologiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains virions, comme ceux de la grippe, peuvent affecter le système nerveux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections virales ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains, éviter les contacts étroits et se faire vacciner sont essentiels."
}
},
{
"@type": "Question",
"name": "Les masques protègent-ils contre les virions ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les masques réduisent la transmission des virions par voie respiratoire."
}
},
{
"@type": "Question",
"name": "Les vaccins sont-ils efficaces contre tous les virions ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, chaque vaccin cible des virions spécifiques et ne protège pas contre tous."
}
},
{
"@type": "Question",
"name": "L'hygiène personnelle aide-t-elle à prévenir les infections ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une bonne hygiène personnelle réduit le risque d'infections virales."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque d'infection virale ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyages peuvent exposer à de nouveaux virions et augmenter le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre les virions ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antiviraux, comme l'oseltamivir, sont utilisés pour traiter certaines infections virales."
}
},
{
"@type": "Question",
"name": "Les antibiotiques sont-ils efficaces contre les virions ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les antibiotiques ne sont pas efficaces contre les infections virales."
}
},
{
"@type": "Question",
"name": "Comment les vaccins agissent-ils contre les virions ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccins stimulent le système immunitaire à reconnaître et combattre les virions."
}
},
{
"@type": "Question",
"name": "Les traitements symptomatiques sont-ils utiles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à soulager les symptômes, mais ne traitent pas l'infection virale."
}
},
{
"@type": "Question",
"name": "Les traitements antiviraux sont-ils toujours efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur efficacité dépend du type de virus et de la résistance virale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une infection virale ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la pneumonie, la déshydratation ou des infections secondaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les virions peuvent-ils causer des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains virions, comme le VIH, peuvent entraîner des maladies chroniques."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont gérées par des traitements symptomatiques et des soins médicaux appropriés."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le virion ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque virion peut entraîner des complications différentes selon l'hôte."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque de complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent être plus vulnérables aux complications des infections virales."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'infection virale ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le système immunitaire affaibli et l'exposition à des porteurs."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il le risque d'infection virale ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affaiblir le système immunitaire et augmenter le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles le risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies chroniques peuvent affaiblir l'immunité et augmenter le risque d'infection virale."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans le risque viral ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des environnements surpeuplés ou insalubres augmentent le risque d'infections virales."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque viral ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut affaiblir le système immunitaire et augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 09/03/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Structural Virology Group, Central European Institute of Technology, Masaryk University, Kamenice 753/5, 62500 Brno, Czech Republic.
Publications dans "Virion" :
3 publications dans cette catégorie
Affiliations :
Structural Virology Group, Central European Institute of Technology, Masaryk University, Kamenice 753/5, 62500 Brno, Czech Republic pavel.plevka@ceitec.muni.cz.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Structural Virology Group, Central European Institute of Technology, Masaryk University, Kamenice 753/5, 62500 Brno, Czech Republic.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Department of Zoology, Fishery, Hydrobiology, and Apidology, Faculty of Agronomy, Mendel University in Brno, Zemědělská 1/1665, 613 00 Brno, Czech Republic.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Cellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London, United Kingdom.
Department of Infectious Disease, Imperial College, London, United Kingdom.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Central European Institute of Technology, Masaryk University, Kamenice 753/5, Brno, 625 00, Czech Republic.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Waksman Institute for Microbiology, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, 19107, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Department of Cell Biology and Neuroscience, Rowan University School of Osteopathic Medicine at Stratford, Stratford, NJ, 08084-1489, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, 20894, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, 20894, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, 121205, Russia. maria.sokolova@mpinat.mpg.de.
Department of Molecular Biology, Max Planck Institute for Multidisciplinary Sciences, Göttingen, 37077, Germany. maria.sokolova@mpinat.mpg.de.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Department of Microbiology & Cell Biology, Montana State Universitygrid.41891.35, Bozeman, Montana, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Department of Microbiology & Cell Biology, Montana State Universitygrid.41891.35, Bozeman, Montana, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Department of Microbiology & Cell Biology, Montana State Universitygrid.41891.35, Bozeman, Montana, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Weizmann Institute of Science, Rehovot 7610001, Israel.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Weizmann Institute of Science, Rehovot 7610001, Israel.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Weizmann Institute of Science, Rehovot 7610001, Israel.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
California Institute of Technology, Pasadena, CA 91125, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
California Institute of Technology, Pasadena, CA 91125, USA.
Chan Zuckerberg Biohub, 499 Illinois Street, SF CA 94158, USA.
Publications dans "Virion" :
2 publications dans cette catégorie
Affiliations :
Weizmann Institute of Science, Rehovot 7610001, Israel.
Publications dans "Virion" :
The combination of oxaliplatin and fluoropyrimidine for 6 months is one of the standard options for adjuvant therapy for high-risk stage II and III colorectal cancers (CRCs). The optimal duration of o...
This open-label, randomized, phase III, noninferiority trial randomly assigned patients with high-risk stage II and III CRC to 3 and 6 months of oxaliplatin with 6 months of fluoropyrimidine groups (3...
In total, 1,788 patients were randomly assigned to the 6-month (n = 895) and 3-month (n = 893) arms, and 83.6% in the 6-month arm and 85.7% in the 3-month arm completed the treatment. The neuropathy r...
This study suggests that adding 3 months of oxaliplatin to 6 months of capecitabine could be considered an alternative adjuvant treatment for stage III CRC (ClinicalTrials.gov identifier: NCT01092481)...
It is generally accepted that adjacent guanine residues in DNA are the primary target for platinum antitumor drugs and that differences in the conformations of the Pt-DNA adducts can play a role in th...
To verify whether the intensification of the upfront chemotherapy backbone with a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFOXIRI) increases the activit...
TRIPLETE was a prospective, open-label, phase III trial in which previously untreated patients with unresectable...
From September 2017 to September 2021, 435 patients were enrolled (control group/experimental group: 217/218) in 57 Italian sites. One hundred sixty (73%) patients treated with mFOLFOXIRI plus panitum...
The intensification of the upfront chemotherapy backbone in combination with panitumumab does not provide additional benefit in terms of treatment activity at the price of increased gastrointestinal t...
Oxaliplatin has become the mainstay of treatment for many cancers, but its use can be accompanied by unusual side effects....
We describe herein a 74-year-old patient with pancreatic cancer who developed severe motor weakness affecting lower extremities after starting treatment with oxaliplatin on three separate occasions. O...
Oxaliplatin had to be discontinued due to suboptimal tolerance and a short-lived clinical response. After discontinuation of oxaliplatin, she did not experience any more similar symptoms. A score of 9...
Rare reports of stroke-like events have previously been described with oxaliplatin. While the exact mechanism of these phenomena is not known, alterations in neuronal sodium channels might be involved...
Adjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin-based chemotherapeutic regimens for e...
We examined 138 Japanese patients who received adjuvant CAPOX therapy for high-risk stage II or III CRC between July 2010 and June 2021 at our hospital. Patients were divided according to an age of 70...
Twenty-three patients (17%) were ≥70 years old. Male patients were predominant in the ≥70 years group (p = 0.006). Patients ≥70 years old had more comorbidities (diabetes, p = 0.014; cardiovascular di...
Adjuvant CAPOX therapy was tolerable in elderly Japanese patients. The prognosis of elderly patients with stage III CRC was similar to that of their younger counterparts. Advanced age itself may not b...
DNA double‑strand break repair is critically involved in oxaliplatin resistance in pancreatic ductal adenocarcinoma (PDAC). Hepatocyte nuclear factor 1 homeobox A (HNF1A) has received increased attent...
Oxaliplatin is a common drug used in the management of colorectal malignancies. Rare neurological side effects including amaurosis fugax, urinary retention, stroke, cranial nerve palsy, dysarthria, an...
Oxaliplatin, similar to Cisplatin, exhibits anticancer activity by interacting with DNA and inducing programmed cell death. It is biotransformed through a number of spontaneous and non-enzymatic proce...
Colorectal cancer (CRC), the most common cancer type, causes high morbidity and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have short overall survival. Thus, identif...
A proteomic screen was performed to reveal altered protein kinase phosphorylation in oxaliplatin-resistant (OR) CRC tumour spheroids. The function of CHK2 was characterised using several biochemical t...
We revealed that the level of phospho-CHK2(Thr68) was elevated in OR CRC cells and in ~30% of tumour samples from patients with OR CRC. We demonstrated that oxaliplatin activated several phosphatidyli...
Our findings suggest that CHK2 activity is critical for modulating oxaliplatin response and that CHK2 is a potential therapeutic target for OR CRC....
Resistance to chemotherapy is the deadlock in cancer treatment. In this study, we used wild-type LOVO (LOVO...